Added 4 months ago Drug news
Recordati announces the completion of an agreement with Mylan for the acquisition of the rights to Cystagon (cysteamine bitartrate), indicated...
Added 1 year ago Drug news
The European Union Commission grants marketing authorization for Cystadrops 3.8mg/mL. for treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.- Recordati
Recordati announces that the European Union Commission has granted the European marketing authorization for its orphan medicinal product Cystadrops 3.8mg/mL....
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Discover an overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
The 2011 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerulonephritis (GN) aims to assist practitioners caring for adults and children with GN.
Added 6 years ago
Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors.
Introduction: There was no report of nephrotoxicity during clinical trials assessed sofosbuvir for treatment of hepatitis C (HCV) infection. This may be due to excluding patients with severe kidney dysfunction...
Added 15 days ago
Fcγ Receptor IIIa Single–Nucleotide Polymorphisms and Haplotypes Affect Human IgG Binding and Are Associated With Lupus Nephritis in African Americans
Objective:To investigate whether the Fcγ receptor IIIa–66L/R/H (FcγRIIIa–66L/R/H) polymorphism influences net effective receptor function and to assess if the FCGR3A...
Added 4 years ago
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
Objective:To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN).Methods:Patients were randomized 1:1:1 to...
Added 4 years ago